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Abstract
Background: Strictly intravascular approaches for the treatment of postangioplasty restenosis are
effective in the intima and the inner parts of the media but may be insufficient to control redundant
pathways in the more outer parts of the media and the adventitia. An inverse situation may occur
subsequently to a strictly extravascular approach, like the recently suggested pericardial approach
in pigs. We hypothesized that simultaneous intra/extravascular administration of anti-restenotic
agents inhibits restenosis by blocking all stimulatory pathways in the entire arterial wall.
Methods: Fresh hearts of 25 domestic pigs were obtained from a local slaughterhouse. Left
anterior descending coronary arteries (LAD) were harvested, cut into cylindric 5 mm segments,
and cultured as ex vivo porcine organ cultures (POCs). After 9 bar ballooning simultaneous intra/
extravascular administration of high dose diltiazem (50 µg/mL) was carried out for a period of 1, 2,
3, 4, 5, 6, and 7 days. At day 7 and 28 proliferative activity (BrdU), neointimal thickening, and
staining against smooth muscle α -actin and vWF was analysed.
Results: 7 days after ballooning administration of diltiazem for 4, 5, 6, and 7 days inhibited reactive
cell proliferation by more than 50% (n.s.) as compared to control, 28 days after ballooning
administration for 6 and 7 days inhibited neointimal thickening by more than 75% (p < 0.05).
Simultaneous intra/extravascular administration of high dose diltiazem did not affect the expression
of vWF in endothelial cells or smooth muscle α -actin in smooth muscle cells.
Conclusions: Simultaneous intra/extravascular administration of high dose diltiazem (50 µg/mL)
has to be maintained for at least 6 days to achieve a significant inhibition of neointimal thickening.
The data demonstrate the importance of the maximal reactive cell proliferation (= day 7 in the
POC-model) for the calculation of the duration of the treatment period.
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Introduction
Despite the outstanding success of coronary angioplasty
and related techniques the problem of restenosis [1] has
not yet been overcome. This is predominantly caused by
the unexpected complexity of the reaction of the coronary
artery wall to a relatively simple aggression with an intra-
vascular device. In a very schematic way the main events
after coronary artery ballooning are dissection, elastic re-
coil, thrombosis, leukocyte attack, reactive cell prolifera-
tion, and arterial remodeling [2]. Among these reactive
cell proliferation remains extremely difficult to control, al-
though many therapeutical agents have a strong antipro-
liferative effect [3]. This may be due to the fact that after
vascular injury a huge amount of signal transduction cas-
cades is activated in the different cell types within the en-
tire arterial wall.
Intravascular anti-restenotic drug regimens are predomi-
nantly effective in the inner layers of the artery wall, up-
regulation of redundant pathways in the outer parts of the
media and the adventia are not or not entirely inhibited.
Therefore we hypothesized that simultaneous intra/ex-
travascular administration of antiproliferative agents in-
hibits restenosis by blocking all redundant pathways [4].
In vivo simultaneous intra/extravascular administration
could be carried out by a combination of drug-eluting
stents with the pericardial approach [5–7].
The domestic pig is the experimental in vivo model that
mimics the characteristic features of human restenosis
most closely [8]. In order to limit the number of obligato-
ry experimental studies we have suggested previously to
employ organ cultures of porcine coronary arteries
(POCs) that had been obtained from a local slaugther-
house [9]. Due to the fact that internal and external surfac-
es of the coronary artery segments in the POC-model have
full contact with the culture medium, simultaneous intra/
extravascular drug therapy can be mimiced easily by add-
ing a potential anti-restenotic agent to the culture medi-
um [4].
In a cascade of various prescreening and complex in vitro
models of human restenosis [10] we have recently dem-
onstrated a significant antiproliferative effect of the calci-
um channel blocker diltiazem in a concentration of 50 µg/
mL, a toxic effect could be excluded. Due to the fact that
this very high concentration is settled two orders of mag-
nitudes above the maximal plasma level subsequent to
systemic administration, it can be achieved barely in a lo-
cal high dose approach. In the POC-model the maximal
reactive cell proliferation after ex vivo ballooning occurres
at day 7, followed by a maximum of neointimal thicken-
ing at day 28 [9]. In the current study we added high dose
diltiazem for 1, 2, 3, 4, 5, 6, and 7 days to the POC-model
and studied, howmany days the antiproliferative regime
has to be maintained in order to accomplish a significant
inhibition of neointimal thickening at day 28.
Methods
Preparation of coronary organ cultures
Fresh hearts of 25 pigs (age 3–5 months, weighing 100–
120 kg) were obtained from a local slaughterhouse. Left
anterior descending coronary arteries (LAD) were pre-
pared and removed carefully from the epicardial surface.
Cylindric segments with a side lenght of 5 mm were cut
from the LAD-segments. Immediately after preparation,
LAD-cylinders were transfered as POC into sterile HEPES-
buffered (15 mmol/L) culture medium (DMEM) without
serum supplement.
Ex vivo ballooning
For ex vivo angioplasty POCs were incubated with a
standard 3 mm balloon catheter (Medtronic 14K2030E,
Diisseldorf, Germany) and treated with 9 bar for 60 s, the
balloon/artery ratio was 1. If tearing occurred in the artery
wall, the segments were not used for the study. The infla-
tion of balloon catheters was carried out with Aqua bidest.
Simultaneous intra/extravascular application of high dose 
diltiazem
After ex vivo ballooning high dose diltiazem (Gödecke,
Freiburg im Breisgau, Germany) was added to the culture
medium in a concentration of 50 µg/mL. The agent was
dissolved in distilled water. Simultaneous intra/extravas-
cular application of high dose diltiazem was carried out
by incubation of POC with diltiazem for a period of 1, 2,
3, 4, 5, 6, and 7 days. At each medium exchange the drug
was renewed.
Cultivation and fixation of organ cultures
Immediately after in vitro ballooning LAD-segments were
transfered to 6 well plates (Tecnomara, Fernwald, Germa-
ny) and cultured in a mixture of Waymouth's MB 752/1
and Ham F12 nutrient mixture (1:1 v/v; Bio Whittaker,
Verviers, Belgium) supplemented with 15% fetal calf se-
rum (Bio Whittaker, Verviers, Belgium) at 37°C in 5%
CO2. The culture medium was exchangedevery second or
third day or if diltiazem had to be administered. Culture
conditions for the control groups (angioplasty without
diltiazem and neighter angioplasty nor diltiazem) were
exactly thesame as described for the angioplasty/diltiazem
group.
Analysis of postangioplasty reactive cell proliferation
Paraffin sections were processed for immunohistological
staining using the avidin-biotin immunoperoxidase tech-
nique [9]. Bromodeoxyuridine (BrdU), a thymidine ana-
logue, is incorporated into the DNA of S-phase
proliferating cells. 18 h foregoing fixation of the LAD or-
gan cultures BrdU (20 µM, Serva, Heidelberg, Germany)BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/2
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was added to the culture media supplemented with 20 µM
deoxycytidine (Serva, Heidelberg, Germany) in order to
determine the extent of the cells undergoing DNA synthe-
sis, as described [9]. As secondary antibody a biotinylated
horse-anti-mouse antibody (Camon, Wiesbaden, Germa-
ny) was used. The number of proliferating cells in the me-
dia and in the neointima was calculated independendly
as: Number of BrdU-positive cells/Total cell number ×
100. Only sections cut perpendicular to the vessel wall
axis were used for the analysis, five sections from different
LAD segments were evaluated microscopically in each sin-
gle experiment at a magnification of ×  40.
Identification of smooth muscle cells
Smooth muscle cells (SMC) were identified by positive
staining of sections with antibodies against smooth mus-
cle α -actin (Renner, Darmstadt, Germany) at a concentra-
tion of 1 µg/mL. The detection of the primary antibody
was carried out in thesame way as described for the BrdU
antibody (see above).
Identification of endothelial cells
Endothelial cells (EC) in sections of organ cultures were
identified by positive staining with antibodies against von
Willebrand factor (vWF, INCSTAR, Stillwater, USA). The
detection of the primary antibody was carried out in the-
same way as described for the BrdU antibody (see above).
Morphometric analysis of neointimal hyperplasia
For histological examination deparaffinized sections were
stained with a modified elastica-van Gieson staining
(Chroma, Köngen, Germany). For calculation of the aver-
age arterial wall thickening after ex vivo ballooning five
cuts from different organ culture segments were analyzed
three times for each single experiment with a computer-
ized digital image analyzer (Bioquant TM System 4 R + M
Biometrics, Bilancy Consulting, Düsseldorf, Germany).
Taking into account the various lumina of POC segments,
the percentage of neointimal thickening was calculated as:
Area of neointima/Area of neointima and media ×  100.
Statistical analysis
Data are presented as mean ± S.D. The two-tailed U-test of
Mann, and Whitney was used for determining statistical
significance of differences. Statistical significance was ac-
cepted for P < 0.05 [11].
Results
Effect of simultaneous intra/extravascular administration 
of high dose diltiazem on reactive postangioplasty cell pro-
liferation
The effect of simultaneous intra/extravascular administra-
tion of high dose diltiazem on relative reactive cell prolif-
eration both in the neointima and the media of POC
segments was studied 7 and 28 days after ex vivo balloon-
ing.
Seven days after ex vivo ballooning in the neointima a
39.4 fold increase of proliferative activity (n.s.) was detect-
ed, the number of BrdU-positive cells was increased from
0.1 ± 0.34% in untreated controls to 4.3 ± 5.6% (Fig. 1
and 2). After simultaneous intra/extravascular administra-
tion of diltiazem for 1 and 2 days the number of BrdU-
positive cells was 2.8 ± 6.1% and 1.1 ± 1.8% correspond-
ing to an inhibition by 36 respectively 75%. Administra-
tion of diltiazem for 3 days resulted in an increase of
BrdU-positive cells by 52%, 6.6 ± 10.4% of BrdU-positive
cells were detected. After incubation of POC-segments
with diltiazem for 4, 5, 6, and 7 days the percentage of
BrdU-positive cells was 0.8 ± 1.1%, 1.9 ± 3.6%, 0.3 ±
0.7%, and 1.2 ± 1.8% corresponding to an inhibition by
81%, 57%, 93%, and 72%. 28 days after ballooning the
number BrdU-positive cells was very small, 0.0 ± 0.0% of
BrdU-positive cells were detected in untreated controls
and in the POC balloon-group. Incubation with diltiazem
for 1, 2, and 3 days resulted in 0.0 ± 0.0%, 1.2 ± 2.6%, and
0.1 ± 0.2% of BrdU-positive cells, respectively. 28 days af-
ter incubation with diltiazem for 4, 5, 6, and 7 days the
number of BrdU-positive cells was 2.2 ± 5.9%, 3.2 ± 7.2%,
0.0 ± 0.0%, and 1.1 ± 2.4%.
In the media the number of BrdU-positive cells was al-
ways very low, no matter whether or not cells were incu-
bated with diltiazem or treated with the balloon or both.
7 days after ballooning 0.0 ± 0.0% of BrdU-positive cells
were detected in untreated controls, 0.2 ± 0.2 after 9 bar
ballooning. Incubation with diltiazem for 1, 2, and 3 days
resulted in 0.1 ± 0.0%, 0.0 ± 0.0%, and 0.7 ± 1.3% of
BrdU-positive cells. After incubation with diltiazem for 4,
5, 6, and 7 days the number of BrdU-positive cells was 0.0
± 0.0%, 0.1 ± 0.2%, 0.1 ± 0.1%, and 0.0 ± 0.0%. 28 days
after ballooning 0.0 ± 0.0% were found in untreated con-
trols and after 9-bar ballooning. Incubation of POC-seg-
ments with diltiazem for 1, 2, and 3 days resulted in 0.1 ±
0.1%, 0.1 ± 0.2%, and 0.0 ± 0.0% of BrdU-positive cells,
after incubation for 4, 5, 6, and 7 days 0.1 ± 1.4%, 0.1 ±
0.3%, 0.1 ± 0.1%, and 0.2 ± 0.4%.
No statistical significance was reached seven and 28 days
after ballooning between the number of BrdU-positive
cells in the balloon-group in comparison to the balloon/
diltiazem group.
Effect of simultaneous intra/extravascular administration 
of high dose diltiazem on neointimal thickening
The effect of simultaneous intra/extravascular administra-
tion of high dose diltiazem on relative neointimal thick-
ening was analysed 7 and 28 days after 9 bar ballooning
(Fig. 3 and 4).BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/2
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Figure 1
Effect of simultaneous intra/extravascular administration of high dose diltiazem (50 µg/mL) for 1 – 7 days on time course of
cells undergoing DNA synthesis in coronary organ cultures 7 (A) and 28 days (B) after ex vivo ballooning. The number of cells
in the neointima with positive bromodeoxyuridine incorporation is depicted in relation to the total cell number.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/2
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Figure 2
Micrographs showing serial sections of porcine coronary organ cultures at day 7, staining with BrdU (avidin /biotin method):
untreated control (A), ex vivo ballooning (B)and ex vivo ballooning with simultaneous intra/extravascular antiproliferative drug
therapy (C). arrows = cells with positive staining against BrdU.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/2
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Figure 3
Effect of simultaneous intra/extravascular administration administration of high dose diltiazem (50 µg/mL) for 1 – 7 days on
neointimal thickening in porcine organ cultures 7 (A) and 28 days (B) after ballooning. Each column represents five different
vessels, * = p < 0.05.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/2
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Figure 4
Micrographs of sections of porcine coronoary organ cultures at day 28, staining with elastica van gieson: untreated control (A),
ex vivo ballooning (B) and ex vivo ballooning with simultaneous intra/extravascular antiproliferative drug therapy (C). arrow =
area of neointimal thickening.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/2
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7 days after ballooning neointimal thickening in the bal-
loon treated group was significantly increased 1.8 fold (p
< 0.05) from 5.5 ± 4.0% in the untreated group to 10.3 ±
4.8%. simultaneous intra/extravascular incubation with
diltiazem for 1 and 2 days caused an inhibition of neointi-
mal thickening by 59% (n.s.) and 21% (n.s.), correspond-
ing to 4.2 ± 3.0% and 8.1 ± 8.8%. After simultaneous
intra/extravascular administration of diltiazem for 3 days
neointimal thickening was increased (n.s) by 24% (12.8 ±
11%). Incubation of POC-segments for 4, 5, 6, and 7 days
resulted in a neointimal thickening of 9.1 ± 6.3%, 4.0 ±
5.0%, 4.0 ± 4.5%, and 3.7 ± 4.1%, corresponding to an in-
hibition (n.s.) by 12%, 61%, 61%, and 64%.
28 days after ballooning neointimal thickening of POC
segments was significantly (p < 0.05) increased 2.6 fold
from 10.5 ± 11.0% in untreated controls to 28.4 ± 17.8%.
No effect was found after incubation with diltiazem for 1
day. Incubation with diltiazem for 2 and 3 days resulted
in an inhibition of neointimal thickening by 25% (n.s.)
and 86% (p < 0.05), corresponding to 21.2 ± 10.0% and
4.1 ± 5.9%. After Incubation of POC-segments for 4, 5, 6,
and 7 days with diltiazem neointimal thickening was in-
hibited by 73%, 53%, 82% (p < 0.05) and 76% (p < 0.05),
corresponding to 7.7 ± 8.8%, 13.3 ± 8.0%, 5.1 ± 10.2%,
6.8 ± 12.1%.
Identification of smooth muscle and endothelial cells
In the media of POC segments staining with antibodies
against smooth muscle α -actin was always positive, no
matter whether or not organ cultures were treated with
ballooning or diltiazem or both. The number of smooth
muscle α -actin positive cells in the media decreased with
increased time in culture, only few POC-segements
stained positive after 28 days in culture. In the neointima
of POC segments staining against smooth muscle α -actin
was negative after ballooning and negative after balloon-
ing and EP diltiazem incubation.
Staining of POC-segments with antibodies against vWF
was always positive in untreated controls, but decreased
after ballooning, simultaneous intra/extravascular incu-
bation with high dose diltiazem did not further decrease
the number of cells with positive staining against vWF.
Discussion
Simultaneous intra/extravascular administration of anti-
proliferative agents is in a way the maximal strategy to in-
hibit all pathways that might have been activated after an-
gioplasty. This ex vivo study demonstrates two major
findings: 1) the POC-model is a suitable model to study
this maximal antiproliferative strategy, and 2) the simul-
taneous intra/extravascular antiproliferative approach has
to be maintained for 6 or 7 days, if a significant inhibition
of neointimal thickening shall be achieved. This period of
time is almost identical with the peak of reactive cell pro-
liferation in the POC-model [9].
Activation of SMC proliferation and migration after angi-
oplasty via abundant stimulatory pathways is not re-
strained to inner layers of the vessel wall. Recently Ciezki
et al. [12] have reviewed autopsy records of patients who
received PTCA prior to death. The authors located sites of
cellular proliferation by immunohistochemical staining
and demonstrated that reactive cell proliferation after
PTCA was found throughout the treated arterial section's
axial plane. An anti-restenotic approach that is adminis-
tered selectively from the intravascular surface of a dilated
artery will inhibit mainly stimulatory pathways that acti-
vate SMC proliferation and migration in the inner layers
of the artery wall but will fail to inhibit stimulatory path-
ways in the outer parts of the media and in the adventitia.
This may explain why local antiproliferative strategies that
are administered via selective endoluminal delivery sys-
tems as e.g. the Scimed Dispatch Coronary Infusion Cath-
eter failed to inhibit experimental restenosis [13].
A new dimension of antiproliferative drug therapy has
been opened by suggestions to use the pericardium as an
perivascular drug depot [5–7]. Verrier reported of a suc-
cessful transatrial access to the normal pericardial space in
6 dogs and 13 pigs [5], Laham et al. [6] demonstrated in
49 yorkshire pigs a safe subxyphoid access. First clinical
experiences with the subxiphoid access have been report-
ed lately by Macris et al. [7]. Although the pericardial ap-
proach is a very encouraging technique that will acquire
its place in the treatment of restenosis within the next
years it should be kept in mind that a strictly extravascular
approach may produce the inverse situation that stimula-
tory pathways of reactive cell proliferation are inhibited in
the adventia and the more distal parts of the media but
not in the neointima and the inner parts of the media. The
simultaneous intra/extravascular administration of anti-
proliferative agents is likely to inhibit consequently all
stimulatory pathways in the entire injured artery wall.
Coronary arteries of domestic pigs respond in a similar
way to vascular injury as do human coronary arteries [8].
In order to reduce the number of indispensable animal
studies we characterized in a previous study a model of
restenosis with coronary organ cultures of domestic pigs
obtained from a local slaughterhouse [9]. In these POCs
the maximal reactive proliferation of SMC occurred at day
7 after ex vivo ballooning, the maximal neointimal thick-
ening was detected at day 28. By adding of antiprolifera-
tive agents to the culture medium POCs progress to an
elegant ex vivo model for studies of simultaneous intra/
extravascular drug administration [4], because both intra-
vascular and extravascular surfaces of the 5 mm cylindricBMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/2
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organ culture segments have full contact with the agents
administered to the culture medium.
In POCs reactive cell proliferation after ex vivo ballooning
was reduced by more than 50% after simultaneous intra/
extravascular administration of diltiazem for 4, 5, 6 or 7
days (n.s.), neointimal thickening was significantly inhib-
ited after high dose diltiazem incubation for 6 or 7 days.
A strong inhibitory effect of diltiazem is in accordance
with prior reports of our laboratory that diltiazem in a
concentration of 50 µg/mL significantly inhibited reactive
cell migration and proliferation in various in vitro models
of human coronary restenosis [10]. Clinical studies apply-
ing diltiazem as anti-restenotic agent after peroral admin-
istration have not been successful [14,15], with the
exception of one study [16] that has only been reported as
an abstract. Peak plasma levels of diltiazem are approxi-
mately 0.12 µg/mL after a 90 mg dose and 0.15 µg/mL af-
ter a 120 mg/dose [17], the administered dosage of
diltiazem in these clinical studies varied between 90 mg
twice a day [16] and 120 mg three times a day [15]. The
negative results of systemically administered diltiazem in
these clinical studies was not surprising, because plasma
levels were settled more than two orders of magnitudes
below the concentrations required for a significant anti-
proliferative effect [10].
In accordance with prior reports of Koo and Gotlieb [18]
and our laboratory [9] staining against smooth muscle α -
actin in the media was constantly clearly positive. Simul-
taneous intra/extravascular incubation of POCs with
diltiazem in a concentration of 50 µg/mL did not convert
the α -actin structures of SMC in the media. These data are
supported by the fact that diltiazem in concentration of
50  µg/mL did not alter the cytoskeletal structures of
smooth muscle α -actin, vimentin, and α -tubulin struc-
tures in human coronary SMC in vitro [10]. Staining
against smooth α -actin in the neointima was negative at
day 7 and day 28. Kocher et al. [19] have suggested that
one possible explanation for this phenomenon may be
that actively proliferating SMC express a different F-actin
phenotype from the α -isoform recognized by the smooth
muscle α -actin antibody. This explanation is confirmed
by the fact that reactive cell proliferation in the POC was
very low in the media but increased in the neointima.
Staining of POC-segments with antibodies against vWF
was always positive in untreated controls, but decreased
after ballooning. This result is in accordance with the hy-
pothesis that endothelial injury is an important stimulus
for reactive cell proliferation after angioplasty. EC did not
recover after beeing damaged during the ballooning, the
number of vWF factor positive cells was identical 7 and 28
days after ballooning. The missing recovery of EC in POCs
was probably predominantly caused by the fact that we
did not use EC-specific culture medium. Simultaneous in-
tra/extravascular administration of high dose diltiazem
for up to seven days did not further decrease the number
of vWF positive cells. This may be substantial for a suffi-
cient re-endotheliazation of the inner vessel wall after an-
gioplasty in vivo.
The uncertain correlation between data of in vitro and in
vivo studies on one side and animal and human species
on the other side is a fundamental problem of restenosis
research. We have recently demonstrated in 3D human
coronary in vitro model [20] that the positive effects of as-
pirin in early atherosclerosis and restenosis can only be
achieved if a concentration of 5 mM is administered, more
than 10-times the commonly administered oral dosage.
Although the ex vivo POC-model is very close to the in
vivo situation in the domestic pig [21], potential prob-
lems may arise by the absence of blood flow, blood pres-
sure and shear stress, kidney or liver activities. Therefore
the significant inhibition of neointimal hyperplasia in the
POC-model after simultaneous intra/extravascular ad-
ministration of 50 µg/mL of diltiazem has to be consid-
ered as an absolute minimum. It may be neccessary to
increase both the period of administration and the con-
centration of diltiazem in order to reproduce an antipro-
liferative effect in vivo.
Although the domestic pig mimics the human situation
very closely major differences endure between porcine
and human tissue. Lately our laboratory has demonstrat-
ed [22] that the maximal proliferative response after ex
vivo ballooning in human organ cultures of renal arteries
(HOCs) occurred at day 21 after ballooning, followed by
a maximum of neointimal thickening at day 56. These
POC/HOC species differences with a maximum of anti-
proliferative activity at day 7/21 and a maximum of ne-
ointimal hyperplasia at day 28/56 will be of extreme
importance if the time period of simultaneous intra/ex-
travascular administration of diltiazem in humans shall
be estimated in the future.
The ex vivo POC-model [9] has the unique advantage that
it can be compared easily to an in vivo model of thesame
species, the domestic pig [21]. Both in the ex vivo POC-
model [9] and the in vivo domestic pig model [21] the
maximal reactive cell proliferation and the maximal ne-
ointimal thickening after vascular injury occures at thesa-
me days: day 7 respectively day 28. It might be speculated
that the similarities between the data of the ex vivo POC-
model and the in vivo domestic pig model can be discov-
ered as well between the ex vivo HOC-model and the sit-
uation of the clinical patient after angioplasty. The
unknown in vivo situation of the clinical patient might
therefore be calculated or at least approached by the three
understood variables. If that hypothesis is confirmed byBMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/2
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other groups and by our own future research the combi-
nation of the in vivo domestic pig model with the ex vivo
POC- and HOC-models may offer the closest approach to
human coronary artery restenosis so far described.
The ex vivo/in vivo analogous conclusion can be applied
to approach the reaction of human coronary arteries in
the clinical patient after simultaneous intra/extravascular
administration of high dose diltiazem. Data of the study
presented would correspond to variable 1, data of variable
2 and 3 are not yet available. Therefore the following stud-
ies should be carried out in the near future: 1) simultane-
ous intra/extravascular administration of diltiazem in the
domestic pig for a period of 7 days, detection of reactive
cell proliferation and neointimal thickening at day 7 and
day 28, and 2) simultaneous intra/extravascular adminis-
tration of diltiazem in the ex vivo HOC-model for a peri-
od of 21 days and detection of reactive cell proliferation
and neointimal thickening at day 21 and day 56.
Analogous conclusions based on the relation between ex
vivo/in vivo domestic pig models and the ex vivo HOC-
model have the potential to abridge porcine/human spe-
cies differences. Due to the significant importance of this
hypothesis we would like to encourage other groups in the
field to focus human restenosis by applying ex vivo POC-
[9] and HOC-models [22] in combination with the in
vivo domestic pig model [21].
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